The reviewed literature showed similar and sometimes improved glycemic control when insulin icodec was compared to other long-acting insulins both in insulin-naive and previously insulin-treated patients with the data being most robust in patients with type 2 diabetes. This evidence concerns the gene INS and type 2 diabetes mellitus.